Central nervous alpha-adrenergic receptors and the mode of action of alpha-methyldopa.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001011:Aorta / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects*; D002395:Catecholamines / Q000037:antagonists & inhibitors; D002415:Cats; D002552:Cerebral Ventricles / Q000502:physiology*; D003042:Cocaine / Q000494:pharmacology; D004298:Dopamine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D007022:Hypotension / Q000139:chemically induced; D007545:Isoproterenol / Q000494:pharmacology; D008750:Methyldopa / Q000494:pharmacology*; D009638:Norepinephrine / Q000494:pharmacology; D010477:Perfusion; D010646:Phentolamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D011941:Receptors, Adrenergic; D012110:Reserpine / Q000494:pharmacology; D014439:Tyramine / Q000494:pharmacology; D015016:Yohimbine / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D002395:Catecholamines; D011941:Receptors, Adrenergic; D000804:Angiotensin II; D015016:Yohimbine; D008750:Methyldopa; D012110:Reserpine; D011433:Propranolol; D003042:Cocaine; D007545:Isoproterenol; D004298:Dopamine; D009638:Norepinephrine; D014439:Tyramine; D010646:Phentolamine